A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
← catalyst calendarNCT07793409 · readout in 1,886 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,508estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-28
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-14 | estimated | When the study began enrolling |
| Primary completion | 2031-10-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-10-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Intervention
- Drug: Lunsekimig — also filed as SAR443765
Primary outcomes
what the primary-completion date above is the date OFExposure-adjusted incidence rate of treatment-emergent adverse events (TEAE), including adverse events of special interest (AESI ) and serious adverse events (SAE)
measured Study baseline to Week 100
ICS withdrawal sub-study: Change from Week 12 (end of run-in period) to Week 36 in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1)
measured From Week 12 to Week 36
Related
SNY · their whole pipeline · COPD readouts · Who in Congress owns SNY?
SNY's other studiesmost recently updated first
- The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry — · Recruiting
- Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials Phase 2/3 · Active, not recruiting
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor Phase 3 · Active, not recruiting
- Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration Phase 2 · Active, not recruiting
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 3 · Recruiting
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed